Auditory target processing in methadone substituted opiate addicts: The effect of nicotine in controls by Müller, Bernhard W et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Psychiatry
Open Access Research article
Auditory target processing in methadone substituted opiate 
addicts: The effect of nicotine in controls
Bernhard W Müller*1,2, Michael Specka1, Nicolai Steinchen1, 
Dieter Zerbin1,2, Ernst Lodemann2, Thomas Finkbeiner3 and 
Norbert Scherbaum1,2
Address: 1Clinic for Addictive Behaviour and Addiction Medicine, University of Duisburg-Essen, Virchowstr. 174, 45147 Essen, Germany, 2Clinic 
for Psychiatry and Psychotherapy, Virchowstr. 174, University of Duisburg-Essen, 45147 Essen, Germany and 3Clinic for Psychiatry and 
Psychotherapy, Volksgartenstr. 40, 44388 Dortmund, Germany
Email: Bernhard W Müller* - bernhard.mueller@uni-due.de; Michael Specka - michael.specka@uni-due.de; 
Nicolai Steinchen - nicolai.steinchen@freenet.de; Dieter Zerbin - dieter.zerbin@uni-due.de; Ernst Lodemann - melanie.kownatka@uni-due.de; 
Thomas Finkbeiner - psychiatrie@evk-luedo.de; Norbert Scherbaum - norbert.scherbaum@uni-due.de
* Corresponding author    
Abstract
Background: The P300 component of the auditory evoked potential is an indicator of attention
dependent target processing. Only a few studies have assessed cognitive function in substituted
opiate addicts by means of evoked potential recordings. In addition, P300 data suggest that chronic
nicotine use reduces P300 amplitudes. While nicotine and opiate effects combine in addicted
subjects, here we investigated the P300 component of the auditory event related potential in
methadone substituted opiate addicts with and without concomitant non-opioid drug use in
comparison to a group of control subjects with and without nicotine consumption.
Methods: We assessed 47 opiate addicted out-patients under current methadone substitution and
65 control subjects matched for age and gender in an 2-stimulus auditory oddball paradigm. Patients
were grouped for those with and without additional non-opioid drug use and controls were
grouped for current nicotine use. P300 amplitude and latency data were analyzed at electrodes Fz,
Cz and Pz.
Results: Patients and controls did not differ with regard to P300 amplitudes and latencies when
whole groups were compared. Subgroup analyses revealed significantly reduced P300 amplitudes
in controls with nicotine use when compared to those without. P300 amplitudes of methadone
substituted opiate addicts were in between the two control groups and did not differ with regard
to additional non-opioid use. Controls with nicotine had lower P300 amplitudes when compared
to patients with concomitant non-opioid drugs. No P300 latency effects were found.
Conclusion:  Attention dependent target processing as indexed by the P300 component
amplitudes and latencies is not reduced in methadone substituted opiate addicts when compared
to controls. The effect of nicotine on P300 amplitudes in healthy subjects exceeds the effects of
long term opioid addiction under methadone substitution.
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Background
The P300 component of the auditory evoked potential
(ERP) can be derived from the EEG in oddball type exper-
iments when rare task-relevant stimuli are interspersed
into frequently presented non-task related stimuli [1]. The
P300 component of the auditory evoked potential
emerges between 260 ms to 500 ms following the onset of
the target stimulus. The P300 is one of the most robust
components within ERP research and the amplitude of
the P300 component rises with lower objective probabil-
ity and lower subjective certainty about the occurrence of
the target stimulus [2]. The P300 reflects attention
dependent target processing. A recent model on the neu-
ropsychological basis of the P300 by Polich [3] suggests
that a target stimulus initiates frontal lobe activity in the
allocation of attention resources needed to perform the
task associated with the target stimulus and the exchange
of working memory content. Further processes involve the
temporal lobe and the parietal cortex with stimulus repre-
sentation maintenance mechanisms and subsequent
memory storage and updating processes. Therefore, a sim-
ple task to press a button upon the rare occurrence of a
deviant auditory stimulus evokes the initiation of a set of
cognitive functions and their related areas in the brain [4].
Methadone substitution is a treatment for subjects
addicted to opiates, mainly to heroin. Methadone is a syn-
thetic opiate agonist at cerebral µ- and κ-opiate receptors.
If given in a sufficient dose, methadone prevents opiate
addicts from withdrawal symptoms after cessation of her-
oin use [5]. Methadone is taken orally and has an half-life
of about 24 hours, so that usually one single dose per day
is sufficient. When given in therapeutic doses to people
adapted to opiates, methadone exhibits no noticeable
psychotropic effects like sedation or euphoria. Neverthe-
less, the question emerged whether methadone has dete-
riorating effects on cognitive functioning. Previous studies
found impairments in methadone substituted patients
relative to healthy controls with respect to attention, psy-
chomotor speed, working memory and information
processing [6-9]. It is difficult, though, to differentiate the
effects of methadone from other factors, like long term
effects of opiate abuse, effects of former or concomitant
use of other drugs like alcohol, cannabis or cocaine, or
impairments following breath suppression after heroin
overdoses [6,10]. Current studies on cognitive abilities
indicate that methadone-treated opiate addicts perform
better than untreated opiate users, but worse than absti-
nent former opiate addicts [8,11,12].
The auditory P300 has been assessed in a sample of
detoxified opiate addicts with and without methadone
substitution [13]. Compared to controls, both patient
groups showed decreased amplitudes and increased laten-
cies of the P300 component. While in this study the P300
component in methadone substituted the group was less
impaired, this result points to the hypothesis of metha-
done substitution acts as a stabilizing factor in attention
related target processing. In a study by Kouri et al. [14]
opiate addicts were detoxified and then treated with and
without buprenorphine, a partial κ-antagonist and µ-ago-
nist. While the P300 component decreased after detoxifi-
cation in placebo treated subjects, buprenorphine
reversed this decrement to the level of non-dependent
control subjects. While both of these studies used small
sample sizes of seven and ten subjects per group, they
indicate that opiate addicts may show reduced P300
amplitudes with or without substitution [13], and that
substitution treatment may improve auditory target
processing in detoxified opiate addicts [14]. The clinical
relevance of these neurophysiological studies is to gain
insight into whether opiate addicted patients under sub-
stitution treatment show deficits which may impact their
ability to return to or to attain more stable socio-cultural
and occupational settings.
While nicotine use is highly prevalent in methadone sub-
stituted patients, with rates of comorbidity reaching
90%and more [15,16], the effects of nicotine on the P300
component may be confounded with those of opiate
addiction. Chronic nicotine consumption has been found
to be associated with P300 amplitude reduction using a
visual oddball paradigm in a large sample of current
smokers when compared to subjects who never smoked or
those who had terminated smoking [17]. More recently,
Neuhaus et al. (2006), using an auditory oddball para-
digm, reported persistent P300 amplitude reduction in
smokers and furthermore, even in former smokers [18].
Results from these studies indicate that chronic nicotine
consumption is associated with P300 amplitude reduc-
tion, which may confound results when comparing P300
results of nicotine dependent opiate addicts to those of
non-smoking control subjects.
Here we aimed to assess whether methadone substituted
opiate addicts differ from control subjects with regard to
the auditory P300 component in a two-tone oddball
design. Previous studies on the P300 in opiate addicts
used small sample sizes and it remains unclear whether
the P300 is unaffected in a larger group of methadone
substituted opiate addicts when compared to controls. A
second aim was to control for the potentially confound-
ing effect of nicotine consumption in control subjects.
Therefore, we compared the auditory P300 component in
a group of methadone substituted opiate addicts to con-
trol subjects with and without current nicotine consump-
tion.BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
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Methods
We assessed 47 opiate addicted outpatients under current
methadone substitution and 65 control subjects matched
for age and gender. The study was conducted in compli-
ance with the ethical principles for medical research
involving human subjects according to the Declaration of
Helsinki and was approved by the local ethics committee
of the medical department of the University of Duisburg-
Essen. Patients and control subjects gave written informed
consent before study inclusion.
Subjects
Patients had a mean duration of opiate dependency of 9.5
(5.8) years and were under methadone substitution for
19.2 (17.2) month. Patients mean D-L methadone dose
was 92.0 mg (53.3) with a D-L methadone/weight ratio of
1.3 (0.8) mg/kg. Among the 47 Patients, 30 had a con-
comitant non-opioid drug use at the time of assessment
[19]. According to urine analysis at the day of assessment,
nine of these concomitant drug users had consumed ben-
zodiazepines or benzodiazepines and cannabis com-
bined, 13 patients had used cannabis only, 8 patients had
used cocaine with or without additional cannabis or ben-
zodiazepines. Among the 17 patients without non-opioid
drug use, two patients had additional heroin use. Given
the comparable opioid receptor binding of methadone
and heroin, these two patients were included in the opi-
oid group without additional non-opioid consumption.
As evidenced by urine analysis, 65 control subjects had
negative drug screenings, four additional controls with
positive drug screenings were excluded from analysis.
Among the 65 drug-free controls, 30 control subjects were
nicotine consumers, 35 were not. All methadone patients
were nicotine consumers.
Patients and controls did not differ with regard to age
comparing whole groups (t = 0.053, p = 0.96) and sub-
groups of patients with and without concomitant non-
opiate use and controls with and without nicotine con-
sumption (F[3;108] = 0.08, p = 0.98). Gender did not differ
between whole groups (Chi2 = 0.127, p = 0.72) and sub-
groups (Chi2 = 1.05, p = 0.78). The amount of patients
and controls with and without high-school attendance
did not differ statistically (Chi2 = 1.14, p = 0.23). In the
analysis of subgroups however, there was a higher amount
of non-smoking controls with high-school education
(Chi2 = 0.81, p = 0.04).
Patients without concomitant non-opioid drug consump-
tion received a higher dose of methadone than those with
non-opioid drug consumption (mg absolute and mg
dose/weight-ratio, t = 3.67 and t = 3.46, respectively, p <
0.01). The two patient groups did not differ significantly
with regard to years of opiate dependency and duration of
methadone substitution. Details are given in Table 1.
Recruitment and assessment procedure
Subjects took part in a study on cognitive-motor perform-
ance and auditory target processing which altogether
lasted for 2 days. Methadone substituted patients were
recruited from 2 outpatient methadone clinics of a psychi-
atric hospital and from general practitioners. Control sub-
jects were recruited by advertisements in local newspapers
and notices at local job-centers and were financially
refunded for participation. Subjects interested in partici-
pation were invited if they matched the participating
patients with respect to age, gender and educational
attainment.
EEG assessments were performed in the morning of the
second day of the investigation. Subjects were tested for
the absence of alcohol intoxication by means of a breath
analyzer and gave an urine sample. Drug use was assessed
by urine screening for amphetamines, barbiturates, ben-
zodiazepines, cocaine, cannabis, cocaine, heroin and
methadone using fluorescence immunoassay technique
(FPIA, [20]). With the FPIA technique, opiates can be ver-
ified within 2–3 days after consumption, cocaine within
Table 1: Subject characteristics
Methadone substituted opiate addicts Control subjects
whole group without concomitant 
non-opioid drug use
with concomitant 
non-opioid drug use
whole group without nicotine use with nicotine use
N 47 17 30 65 35 30
Age 29.3 (5.6) 28.9 (6.6) 29.6 (5.0) 29.4 (6.1) 29.3 (6.3) 29.6 (5.8)
Gender (m/f) 34/13 11/6 23/7 45/20 25/10 20/10
Education
+ high school 63 3 1 2 1 0 2
- high school 41 14 27 53 25 28
Clinical characteristics:
Duration opiate dep. (y) 9.5 (5.8) 9.3 (7.6) 9.5 (4.8)
Methadone substitution (month) 19.2 (17.2) 20.6 (19.7) 18.4 (15.9)
D-L methadone (mg) 92.0 (53.3) 125 (58) 73 (40)
D-L methadone weight ratio (mg/kg) 1.3 (0.8) 1.8 (0.7) 1.1 (0.7)BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
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2–4 days, benzodiazepines within 2–4 days after a single
consumption and up to 2–3 weeks after chronic con-
sumption. Cannabis can be verified 1 day after a single
consumption and up to 2–3 weeks following chronic con-
sumption. Smoking status was ascertained by self report.
Patients received their methadone dose one hour before
EEG measurements, so that the peak of methadone blood
concentration was reached before the start of the assess-
ment.
P300 evoked potential recording
Subjects were seated in a reclining chair in an electrically
shielded room and were presented randomized auditory
standard (86%, 800 Hz, 65 dBh, 50 ms, 10 ms rise/fall
time) and target stimuli (14%, 1400 Hz, 65 dBh, 50 ms,
10 ms rise/fall time) with an ISI of 3000 (+/- 500) ms.
Subjects had to press a button upon the occurrence of the
target stimulus. EEG recordings were conducted between
8 am and 12 am in patients as well as in control subjects.
EEG was recorded from 19 electrodes (international 10/
20 system, Electrocap Inc.) referenced to linked earlobes
and from two additional bipolar EOG channels (horizon-
tal and vertical) using a Siemens EEG-21 amplifier with
0.2–70 Hz band pass filter (24 dB/octave). EEG-Data were
digitized at 256 Hz from -100 ms to 900 ms relative to
stimulus onsets. Trials exceeding +/- 70 µV in horizontal
or vertical EOG were discarded from analysis.
Digitized EEG trials in the time window between -100 ms
and 900 ms relative to stimulus onsets were baseline cor-
rected and averaged separately for standard and deviant
stimuli using in-house software [21,22]. P300 amplitudes
and latencies were derived from 3 midline electrodes Fz,
Cz, Pz in the range of 260 ms to 500 ms. The mean
number of averaged standard tone sweeps was 288.5
(35.4) in patients and 289.4 (47.5) in controls (p = 0.91).
The mean number of averaged target tone sweeps was
41.0 (5.5) in patients and 43.7 (6.2) in controls (p =
0.02). The amount of standard and target sweeps did not
differ between groups and subgroups.
Statistical analysis
Group comparisons regarding continuously measured
matching criteria and methadone patients' clinical data
were carried out using the independent samples t-test in
case of 2 groups and one-way analysis of variance in case
of 4 groups. Categorial data were analyzed using the Chi-
square test. P300 amplitudes and latencies were analyzed
using repeated measures analysis of variance with elec-
trode as within-subject factor and group membership as
between-subjects factor. For within-subject tests (group ×
electrode interactions), epsilon-corrected averaged F-tests
(Greenhouse-Geisser) were used. While the 4 subgroups
were not parallel with respect to school education, a 4-
level measurement of educational attainment (no attain-
ment, secondary school attainment [the German Haupts-
chul-Abschluss], qualified secondary school attainment
[Realschulabschluss], higher qualifications) was included
as covariate when subgroup membership was the between
subject factor. Results with p < 0.05 were regarded as sig-
nificant. Statistical analyses were carried out using SPSS
v13.0 software.
Results
Behavioral data
Patients made 0.45 (SD 1.06) errors of commission and
0.62 (SD 1.68) errors of omission. Controls made 0.22
(SD 0.60) errors of commission and 0.22 (SD 0.62) errors
of omission. Patients and controls did not differ with
regard to both error types (t-tests with corrections for une-
qual variances, commission errors t = 1.35 and omission
errors t = 1.57 respectively, both p > 0.1). Means of reac-
tion times to target stimuli and the intra-subject standard
deviations of reaction times as a measure of their atten-
tion dependent reaction time stability are given in Table 2.
Patients had non-significantly shorter reaction times than
controls (t = 0.69, p = 0.49). Patients and controls did not
differ in their reaction time dispersion (t = 0.57, p = 0.57).
The comparison of subgroups of patients with and with-
out additional non-opioid drug use and of controls with
and without nicotine use revealed significant differences
between subgroups with regard to reaction time (F[3;108] =
2.85, p = 0.041) and reaction time standard deviations
(F[3;108] = 4.09, p = 0.009). When education was taken into
account, significant subgroup differences remained stable
only with regard to the reaction time dispersion result
(F[3;107] = 3.79, p = 0.013). Effects were due mainly to dif-
ferences between controls: non smoking controls showed
lower intra-subject reaction time variability (F[1;62]= 5.40,
p = 0.023 indicating a higher stability of attention process-
ing over time.
P300 amplitude data
Means and standard deviations of P300 amplitude data
are given in Table 1. A multivariate analysis of variance
with electrode position (Fz, Cz, Pz) as within factor and
group (patients, controls) as between factor indicated no
differences in P300 amplitudes for the group main effect
(F[1;109] = 60.0, p = 0.72) or the group × electrode interac-
tion (F[1.6;168.5] = 1.55, p = 0.22).
The effect of nicotine in controls (with and without) and
the effect of additional non-opioid drug use was assessed
in a repeated measurements ANOVA with group as
between factor and electrodes (Fz, Cz, Pz) as within factor,
see Figure 1. This analysis revealed a significant group
main effect (F[3;107] = 5.07, p = 0.003) but no significant
electrode × group interaction (F[4.6;164.1] = 0.79, p = 0.57)
when controlling for the effect of education (F[1;107] = 3.4,
p = 0.07). Group effects were further evaluated in group ×BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
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electrode follow up analyses. Concomitant non-opioid
drug use versus no concomitant drug use had no effect on
P300 amplitudes (main effect group: p = 0.69, group ×
electrode interaction p = 0.88). Among controls, nicotine
consumption had a major impact on P300 amplitudes
with a significant group effect (p < 0.001) but no signifi-
cant electrode × group interaction. Control subjects with-
out nicotine consumption were not significantly different
from patients with (p = 0.20) or without (p = 0.09) con-
comitant non-opioid drug use. Control subjects with nic-
otine consumption differed significantly from patients
with concomitant non-opioid use (p = 0.02) but not from
those without (p = 0.10). We found no significant group
× electrode interactions in any of these analyses, see Figure
2.
P300 latency data
Means and standard deviations of P300 latency data are
given in Table 1. A multivariate analysis of variance with
electrode position (Fz, Cz, Pz) as within factor and group
(patients, controls) as between factor indicated no differ-
ences in P300 latencies for the group main effect (F[1;109] =
0.09, p = 0.77) or the group × electrode interaction
(F[1.4;135.4] = 2.29, p = 0.12).
The multivariate analysis of variance with 4 subgroups as
between factor and electrodes (Fz, Cz, Pz) as within factor
revealed no group main effect (F[3;107] = 1.45, p = 0.23)
and no significant electrode × group interaction when
controlling for education (F[1;107]  = 0.04, p = 0.85].
Because of the lack of significant effects in the main anal-
yses, we computed no additional follow-up tests.
P300 data and methadone patients' clinical characteristics
Within the patient group, there were no statistically signif-
icant correlations between length of opiate addiction,
length of methadone treatment, methadone dose or
methadone dose per kg bodyweight on the one hand, and
P3 amplitudes or P3 latencies on the other hand (all Pear-
son-coefficients -0.2 < r < 0.2, all p > 0.1).
Discussion
The comparison of methadone substituted opiate addicts
with a group of matched control subjects revealed no sig-
nificant group differences with regard to P300 amplitudes
and latencies indicating no overall differences between
patients and controls. In the analysis of subgroups, nico-
tine use in control subjects was associated with reduced
P300 amplitudes and patients P300 amplitudes were in
between those of smoking and non-smoking controls.
Additional non-opioid drug use in patients had no signif-
icant impact upon P300 amplitudes or latencies. In the
comparisons of controls with and without nicotine with
patients with or without additional non-opioid drug use,
only the comparison of patients with non-opioid drug use
with smoking controls revealed significant differences
with regard to P300 amplitudes. Here, patients with addi-
tional non-opioid drug use had significantly higher P300
amplitudes when compared to smoking controls. Laten-
cies did not differ between groups and subgroups. With
regard to the first aim of our study we found no attenua-
tion of P300 amplitudes or latencies between patients
under methadone substitution treatment and control sub-
jects. With regard to the second aim of our study we found
a significant effect of nicotine in control subjects.
Detoxification in opiate addicts has been associated with
lowered P300 amplitudes when compared to controls and
substitution treatment has been shown to increase P300
amplitudes [13,14]. Regarding cognitive performance,
patients under methadone treatment tend to show lower
performance in measures of attention, memory and exec-
utive function but not in simple reaction time tasks when
compared to controls [8,23]. However, methadone treat-
Table 2: ERP P300 amplitude, latency and reaction time data
Methadone substituted opiate addicts Control subjects
whole group without concomitant 
non-opioid drug use
with concomitant 
non-opioid drug use
whole group without nicotine 
consumption
with nicotine 
consumption
mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd)
P300 Amplitude (µV)
Fz 23.3 (14.3) 22.5 (14.1) 23.8 (15.1) 25.1 (13.3) 30.9 (10.9) 18.3 (12.9)
Cz 27.6 (14.6) 26.5 (15.5) 28.3 (14.2) 26.9 (15.5) 34.2 (12.8) 18.4 (14.1)
Pz 33.4 (12.3) 32.9 (14.4) 33.7 (11.1) 31.7 (14.5) 37.7 (12.7) 24.8 (13.5)
P300 Latency (ms)
Fz 327 (36) 337 (39) 322 (34) 335 (20) 331 (18) 340 (21)
Cz 333 (43) 339 (42) 330 (45) 335 (23) 332 (24) 339 (22)
Pz 339 (40) 348 (33) 333 (44) 339 (29) 339 (26) 338 (32)
Reaction Time (RT)
RT (ms) between subjects 409 (97) 442 (87) 390 (98) 422 (101) 397 (93) 450 (104)
Standard deviation of RT within subjects (ms) 76 (29) 87 (34) 70 (24) 73 (29) 64 (17) 83 (34)BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
Page 6 of 9
(page number not for citation purposes)
ment has been shown to improve memory and psycho-
motor speed [11]. In our study, patient's P300 amplitudes
were in between those of the two control groups. While all
patients in our study were smokers, it may be suggested
that methadone treatment may have heightened P300
amplitudes to some degree over those of nicotine using
control subjects.
With regard to control subjects, we found significant P300
amplitude differences in the comparison of healthy sub-
jects with and without nicotine use. Nicotine users
showed largely reduced P300 amplitudes at the three elec-
trode sites under investigation. Methadone substituted
patients did not differ with regard to concurrent non-opi-
ate drug use and did not differ significantly from control
groups. Patients P300 amplitudes were in between con-
trols with and without nicotine use. Latencies of the P300
component did not differ between groups. With regard to
behavioral data, healthy subjects without nicotine use
showed a low intra-subject reaction-time variability.
Acute nicotine effects have been shown to have positive
effects in experimental studies on learning and memory
functions in animals as well as in humans [24]. With
regard to the visual P300, amplitude increases [25] and
latency decreases [26] have been reported with acute nic-
otine use. In a study on the auditory P300, amplitudes
have been shown to be decreased in smokers after several
hours of abstinence and to be normalized after smoking
[27]. In the Houlihan et al. (1996) study however, neither
amplitudes nor latencies were affected with smoking in
subjects under short time nicotine abstinence [26].
P300 ERP grand average plots Figure 1
P300 ERP grand average plots. ERP grand average plots at electrodes Fz, Cz and Pz (µV) in subgroups of methadone sub-
stituted patients with and without additional non-opioid drug use and in controls with and without nicotine use. Note: accord-
ing to electrophysiological convention negative evoked potential data are shown upwards.BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
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In contrast to acute effects, chronic nicotine use has been
shown to be associated with lower cognitive performance.
Cognitive performance worsened with nicotine absti-
nence especially in those subject to maternal nicotine use
during pregnancy [28,29]. The detrimental effects of
chronic smoking on the P300 have been established in
two large scale studies demonstrating amplitude reduc-
tions with regard to the auditory [18] and the visual P300
[17]. The sample size in the Anokhin study was large and
the authors controlled their results for a couple of addi-
tional confounding factors. Acute nicotine use remained a
predictor of lowered P300 amplitudes and only family
density of alcohol dependency emerged as another inde-
pendent predictor of P300 amplitude. The effects of cur-
rent alcoholism and drug dependence effects vanished
after controlling for nicotine use [17]. While the effect of
sustained nicotine use on the P300 is not new, our study
demonstrates, that nicotine use has to be controlled for in
studies on cognitive function in patient samples. A higher
proportion of nicotine use in patient groups as compared
to controls may act as a confound, indicating differences
between patient and control samples which in fact may be
due to differences in nicotine use.
While in our study P300 amplitudes of substituted, smok-
ing opiate addicts did not differ from smoking or non-
smoking controls, nicotine had a substantial effect on the
P300 in controls. However it remains unclear, whether
chronic nicotine reduces P300 amplitudes or whether
subjects with lower P300 amplitudes are more prone to
nicotine and use it as some form of self medication.
Together with the hypothesis, that opiate and methadone
use may increase P300 amplitudes, our data support the
notion that effects of nicotine, opiates and effects of addi-
tional predisposing factors interact in some complex form
[17]. While the interaction of these factors can not be
modeled within our data, further studies, assessing nico-
tine and opiate withdrawal as an experimental variable in
smoking opiate dependent patients, will be needed to
investigate the differential contributions of nicotine and
opiate use in these patients.
Taken together, the results of our study suggest that the
effect of nicotine among healthy controls exceeds the
effect of concurrent non-opioid drug use among metha-
done substituted opiate addicts. Low P300 amplitudes
and high reaction time variability point to decreases in
auditory target processing in subjects with current nico-
tine use. The fact that we found no electrode × group inter-
actions indicates that the effects of nicotine may be a more
general one and not be related specifically to frontal or
parietal sources of the P300.
When comparing our data to those of previous studies, we
find that our P300 amplitudes are considerably high
[30,31]. As could be expected in an auditory oddball par-
adigm with an active response to target stimuli, ampli-
tudes increased from electrode Fz to Pz. A number of
factors may have contributed to high P300 amplitudes in
our study: A low target probability of 14%, a long inter-
stimulus interval of about 3000 ms, the assessment of
subjects during morning hours and the assessment of a
group of young adults may have added in their effect
upon amplitudes in our study [30,31].
The clinical relevance of altered P300 amplitudes follows
the relevance of the P300 as an indicator of neuronal
activity related to cognitive processing [32-34]. Starting
with McCarthy et al. (1997) a number of studies assessed
the equivalent of the P300 component with functional
MRI [35] and showed that even a simple task which
requires subjects to press a button or to count the occur-
rence of a rare target stimulus activates a complex network
of neuronal generators, with many of related to attention
processing. Functional imaging studies will have to fur-
ther assess the effects of nicotine and nicotine deprivation
on cognitive function which up to now indicate effects on
dorsolateral prefrontal cortex [36,37], which has been
identified as part of the generators of the P300 in fMRI
experiments [4,35].
Mean P300 amplitude at electrode Pz Figure 2
Mean P300 amplitude at electrode Pz. Mean P300 
amplitudes and standard error bars at electrode Pz (µV) in 
patients with and without concomitant non-opioid use and in 
control subjects with and without nicotine use.BMC Psychiatry 2007, 7:63 http://www.biomedcentral.com/1471-244X/7/63
Page 8 of 9
(page number not for citation purposes)
The clinical conclusion of our study is that, as far as the
P300 indexes relevant parts of basal cognitive processes
related to attention, context updating and memory proc-
esses, patients under methadone substitution treatment
are not impaired. Some of the patients, those with addi-
tional non-opioid drug use, even show larger P300 ampli-
tudes than smoking controls. This result adds to the
evidence that methadone substitution treatment may be a
reasonable strategy to give these patients a basis to return
to or to attain more stable socio-cultural and occupational
settings.
Conclusion
In summary, the results of our study revealed that P300
latencies and amplitudes in methadone substituted opiate
addicts are within the range of control subjects variation.
With regard to reaction times we only found an effect of
improved intra-subject reaction time variability in con-
trols without nicotine use. Therefore our data do not sup-
port the notion of a lowered auditory target processing in
methadone substituted opiate addicts, especially when
compared to smoking control subjects. A surprising result
of our study was that the effect of nicotine in healthy con-
trols exceeded the effect of additional non-opiate use
among patients and the patient/control subject group
effects. With regard to the P300 as an indicator of atten-
tion dependent information processing, our results indi-
rectly indicate that nicotine may have more detrimental
effects than a history of opiate addiction when under
methadone treatment. Therefore nicotine use has to be
taken into account in further studies on cognitive per-
formance and information processing in psychiatric
research. Further studies are needed in order to disentan-
gle the differential effects of nicotine and opiates in
patients with substance dependency.
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